Your browser doesn't support javascript.
loading
Psoriasis and its impact on close relatives and partners of patients - A cross-sectional questionnaire study.
Grossschaedl, Katja; Weger, Wolfgang; Graier, Thomas; Salmhofer, Wolfgang; Mrowietz, Ulrich; Wolf, Peter.
Affiliation
  • Grossschaedl K; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
  • Weger W; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
  • Graier T; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
  • Salmhofer W; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
  • Mrowietz U; Psoriasis-Center at the Department of Dermatology University Medical Center Schleswig-Holstein Kiel Germany.
  • Wolf P; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
Skin Health Dis ; 4(3): e355, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38846686
ABSTRACT

Background:

Little is known about the exact impact of psoriasis on the disease burden of close relatives and partners of those affected by the disease.

Objectives:

The aim of this single-centre cross-sectional study was to evaluate the quality of life in psoriasis patients and the impact of disease on partners and close relatives.

Methods:

250 plaque-type psoriasis patients (58.4% males and 41.6% females) with mostly treatment-controlled disease (mean PASI of 1.7 and Dermatology Life Quality Index (DLQI) of 4.1) were recruited from the Psoriasis Registry Austria (PsoRA) and their close relatives and partners were invited to participate in the study. Patient Family Impact Score (PFIS) was calculated from the FamilyPso questionnaire data to establish categories of disease burden in close relatives and partners.

Results:

Valid FamilyPso questionnaires were returned from 153 (61.2%) close relatives and partners. Correlation analysis revealed a significant association between PASI and DLQI (r = 0.512, p < 0.001), PASI and PFIS (r = 0.228, p = 0.006), and DLQI and PFIS (r = 0.210, p = 0.014). An at least small or larger impairment of life quality (DLQI ≥ 2) was observed in 46.7% of psoriasis patients, despite treatment. A small or larger disease burden was detected in nearly 78.7% of the male and 77.3% of the female relatives and partners quantified with categorized PFIS.

Conclusions:

The study revealed a significant impact of patients' psoriasis on the disease burden of close relatives and partners, depending on the severity of PASI and extent of quality of life disruption in patients. The gender of the relatives and partners had no impact on the PFIS.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Skin Health Dis Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Skin Health Dis Year: 2024 Document type: Article